Why BGPT?
logo

Check the Claims Behind an Author

Review an author's claims as they appear in the record: linked experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Explanation



    Felix Kohle is an early-career physician-scientist in autoimmune neuropathy research. Semantic Scholar metrics are low (h-index 2, 8 citations, 7 papers) but OpenAlex reports a broader, fast-growing profile (65 works, h-index 10, 240 citations, ~70 citations in 2026), with first-author preclinical EAN studies, a well-cited narrative review, and multicenter clinical work β€” a rising but not yet established scientific trajectory.


     Long Explanation



    Author Review: Felix Kohle β€” Scientific Strength Assessment

    Citation metrics β€” two divergent profiles. Semantic Scholar lists Felix Kohle with h-index 2, 8 total citations, and 7 papers β€” an evidently under-indexed record given his publication dates span 2017–2026 . OpenAlex records 65 works, 240 citations, h-index 10, and steep recent growth: 23 works and ~70 citations in 2026 alone, with topics concentrated in Medicine, Neuritis, Multiple Sclerosis, and Immunology . The database divergence itself is a known reliability caveat: neither source is exhaustive, and conclusions about early-career authors are inherently provisional.

    Core scientific program: translational autoimmune neuropathy. Kohle's first-author narrative review on repurposing MS immunotherapies for CIDP (227 references, 17 citations) systematically maps B-cell depletion, complement inhibition, BTK inhibitors, cladribine, and FcRn inhibitors, while explicitly cautioning against over-generalization from negative trials (e.g., fingolimod in FORCIDP) and heterogeneous, uncontrolled cohorts . Notably, he reports no competing interests on that paper, though co-authors have industry relationships β€” a point of transparency worth crediting.

    Preclinical rigor. His 2026 ActIIR-antibody study in EAN (31 female Lewis rats, randomized, blinded, dose-finding plus pooled replication) showed improved neuritis-score AUC, grip strength reverted to baseline, partial MNCV rescue, improved gait kinematics, preserved muscle fiber cross-sectional area, and reduced Atrogin-1/MuRF1 β€” while honestly reporting null CMAP differences and unchanged nerve inflammation/myelination . The author-reported limitations β€” only female rats, no ultrastructural axonal morphometry, absent myogenic differentiation markers β€” show commendable self-critical practice. An earlier first-author study of kinesin-5 inhibition in EAN (66 references, 14 citations) established his mechanistic regeneration focus .

    Clinical and biomarker work. His most-cited contribution is the multicenter PROSA seizure registry in Annals of Intensive Care (39 citations), plus a 9-center German CIDP care-quality study, a CSF biomarker comparison study, and serum neurofilament light-chain work for CIDP diagnosis .

    Strengths and blindspots. Strengths: methodological range (clinical scores, electrophysiology, DeepLabCut/AutoGaitA kinematics, LC-MS/MS proteomics, qPCR), transparent null-result reporting, DFG and Cologne Clinician Scientist Program funding, and collaborative networks spanning Cologne, DΓΌsseldorf, Essen, Berlin, and Bochum. Blindspots: small per-group rodent samples (n=4–12), single-sex cohorts, limited independent replication, German-language case reports with one erratum, and no PI-led clinical trials yet. Overall verdict: a competent, rapidly accelerating junior researcher whose potential likely exceeds current metrics, but who has not yet demonstrated independent scientific leadership at scale.



    Feedback:    

    Updated: November 02, 2026

     BGPT Author Review



    Scientific Quality

    60%

    Early-career physician-scientist with a coherent CIDP/EAN program spanning preclinical mechanistic work and multicenter clinical studies. OpenAlex h-index of 10 with 240 citations is respectable for the career stage; Semantic Scholar's h-index 2 shows indexing gaps. No PI-led trials or highly-cited first-author landmark yet; strongest works are 11–39 citations. Methodological breadth is a genuine strength; scale and independence are unproven.



    Communication Quality

    60%

    Papers in indexed international journals with structured abstracts and clear conclusions suggest solid scientific writing. One erratum (NeuroTransmitter 2026) is a minor communication blemish. Heavy reliance on German-language venues (Karpaltunnelsyndrom/CIDP, Zusatzdiagnostik) limits international reach; no evidence of major invited talks or review-authorship breadth beyond one well-cited narrative review.



    Author Novelty

    50%

    Drug-repurposing reviews, biomarker characterization, and registry studies are incremental rather than groundbreaking. The ActIIR antibody strategy in EAN and the kinematic gait-analysis methodology in neuropathy (DeepLabCut/AutoGaitA) add moderate originality to the neuromuscular field, but concepts derive from established literature.



    Scientific Rigor

    70%

    The 2026 ActIIR study used randomized, blinded designs, dose-finding, independent replication, and honest reporting of null results (no CMAP difference, no nerve inflammation change). Limitations: small samples (n=4–12/group), single-sex cohort, absent ultrastructural morphometry, and acknowledged mechanistic gaps. The narrative review explicitly names publication bias and cohort heterogeneity β€” unusually transparent for a review author.

     Analysis Wizard



    Compiling and visualizing Felix Kohle's year-by-year publication and citation trajectory to identify inflection points in his research career.



     Hypothesis Graveyard



    That high h-index predicts current scientific quality: weakened here because Semantic Scholar h-index 2 badly undercounts Kohle's real output, and OpenAlex works-count (65) includes many minor German-language papers β€” raw metrics over- AND under-state quality.


    That the ActIIR effect acts via reduced nerve inflammation: directly falsified by the study's own null immunohistochemistry and myelination findings at 30 dpi; the mechanism is downstream, likely muscle-atrophy signaling.

     Science Art


    Author Review: Felix Kohle Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT